ABVC 바이오파마(ABVC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.17 (+1.74%), 시가총액 $0.03B, 52주 최저~최고 $0.91 ~ $4.74.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in
ABVC 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
ABVC 바이오파마의 현재 주가는 $1.17 (+1.74%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
ABVC 바이오파마의 시가총액은 약 $0.03B입니다.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is i